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Diabetic nephropathy (DN) is the leading cause of end stage renal disease worldwide. Increased glucose flux into the aldose
reductase (AR) pathway during diabetes was reported to exert deleterious effects on the kidney. The objective of this study
was to investigate the renoprotective effects of AR inhibition in high glucose milieu in vitro. Rat renal tubular (NRK-52E) cells
were exposed to high glucose (30mM) or normal glucose (5mM) media for 24 to 48 hours with or without the AR inhibitor
epalrestat (1휇M) and assessed for changes in Akt and ERK1/2 signaling, AR expression (using western blotting), and alterations
in mitochondrial membrane potential (using JC-1 staining), cell viability (using MTT assay), and cell cycle. Exposure of NRK-52E
cells to high glucose media caused acute activation of Akt and ERK pathways and depolarization of mitochondrial membrane at 24
hours. Prolonged high glucose exposure (for 48 hours) induced AR expression and G1 cell cycle arrest and decreased cell viability
(84% compared to control) in NRK-52E cells. Coincubation of cells with epalrestat prevented the signaling changes and renal cell
injury induced by high glucose.Thus, AR inhibition represents a potential therapeutic strategy to prevent DN.
1. Introduction
Diabetic nephropathy (DN) is the leading cause of end stage
renal disease worldwide [1]. Chronic hyperglycemia causes
progressive kidney damage in diabetic patients, which is
characterized by three main findings: (1) persistent albumin-
uria (more than 300mg/day or more than 200휇g/min), (2)
progressive and irreversible decline in glomerular filtration
rate (GFR), and (3) increased arterial blood pressure [2].
In most DN cases, pathological changes are prominent
in the glomeruli as well as the renal tubules of diabetes
patients’ kidneys even before the onset of microalbuminuria.
In the glomeruli, the early adaptive changes are marked by
glomerular hypertrophy and thickening of the glomerular
basement membrane (GBM). As the disease progresses, the
mesangial matrix expands, and the mesangial cells increase
in size, leading to glomerulosclerosis and the development
of nodular lesions also known as Kimmelstiel-Wilson nod-
ules, a hallmark of DN. Similarly, the tubules also undergo
early hypertrophy and thickening of the tubular basement
membrane (TBM), which then progress to tubulointerstitial
fibrosis and inflammation at later stages of the disease [3].
Growing body of evidences has shown that DN is
induced by multiple factors such as impaired glucose sig-
naling, increased blood pressure, imbalance in the cellular
redox status, inflammation and altered protein folding, and
turnover within the renal cells. Additionally, several signaling
pathways are implicated in the development and progression
of DN [4]. Akt, a 57KDa serine/threonine kinase that
regulates numerous cellular functions such as transcription,
translation, cell proliferation, and survival, is thought to
play a critical role in induced complications [5]. It has been
shown that Akt increases the production of extracellular
matrix (ECM) proteins such as collagen-I, collagen-IV, and
laminin in diabetic kidney [6, 7]. In addition, the activation
of PI3K/Akt pathway in renal tubules has been shown to cause
tubular hypertrophy via two mechanisms: (1) by a cell cycle-
dependent mechanism and (2) by altering protein translation
through phosphorylation of the protein translation regulator
4E-BP1 [8–10].
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The extracellular signal-regulated kinase (ERK) pathway
is another crucial signaling network involved in numerous
cellular processes [11]. Under hyperglycemia, the Ras-Raf-
MEK-ERK signal transduction cascade becomes activated
and leads to the activation of renin-angiotensin-aldosterone-
system (RAAS), which is well known to cause renal injury
[4, 12]. Moreover, ERK has been shown to induce vascular
endothelial growth factor (VEGF) and transforming growth
factor-beta 1 (TGF-훽1), which causes albuminuria, increase
in GFR, and kidney fibrosis [4, 10, 13]. Furthermore, several
studies have showed crosstalk between ERK pathway and
other pathways in DN such as advanced glycation end
products (AGE) and protein kinase C (PKC) pathways [14].
Therefore, ERK activation is considered one of the significant
signaling events in DN.
Aldose reductase (AR; EC 1.1.1.21) is a member of aldo-
keto reductase (AKR) superfamily [15], which constitutes
more than 100 structurally related proteins [16]. AR is the
rate-limiting enzyme in the polyol pathway, which is respon-
sible for the reduction of glucose to sorbitol using NADPH
as a cofactor. Subsequently, sorbitol is converted to fructose
by sorbitol dehydrogenase using NAD+ as a cofactor. In
normoglycemic conditions, glucose serves as a poor substrate
for AR due to the high Km values of AR for glucose.
Under hyperglycemic conditions, there is increase in flux of
glucose through polyol pathway, which leads to imbalances
in cofactors and products causing several deleterious effects
such as osmotic stress, oxidative stress, increased AGE, and
activation of PKC pathway [17].
Many studies have investigated the role of polyol pathway
in the development of DN and evaluated the protective role
of various aldose reductase inhibitors (ARIs) [18–24]. ARIs
are thought to exert their beneficial effects by decreasing
hyperfiltration, albuminuria, and accumulation of ECM pro-
teins (antifibrotic effects) without affecting the blood glucose
or HbA1c levels [25]. In addition, plethora of in vitro data
supports the link between polyol pathway and PKC activity
and TGF-훽1 and ECM protein production, which suggest the
involvement of this pathway in fibrotic changes observed in
DN [26–29]. Although several preclinical studies using ARIs
have demonstrated nephroprotective effects against DN, the
results from most clinical trials are not very encouraging
[25].There are several challenges to be faced when targeting
AR enzyme including the difficulty of developing ARIs
with high specificity towards ALR2 isoform and the use of
optimum doses for AR inhibition. Moreover, the efficacy of
ARIs depends on the levels of expression of AR in target
tissues and the degree of involvement of polyol pathway
in the development of diabetic complications, which varies
significantly across diabetic patients [25, 30].
In this study, we have investigated the effects of high
glucose concentrations on rat renal proximal tubular cells
cultured in vitro. The study is aimed to investigate the key
molecular pathways that are activated in renal cells under
high glucose conditions and to identify the cellular markers
that mediate hyperglycemia-induced renal cell injury. We
hypothesized that exposing renal tubular cells to high glu-
cose concentrations would induce AR expression and, thus,
inhibiting AR using epalrestat (a potent ARI) would confer
protection against high glucose-induced renal cell injury.
2. Materials and Methods
2.1. Cell Culture. Normal rat kidney cells (NRK-52E; Health
ProtectionAgency,UK)were cultured inDulbecco’smodified
Eagle medium (DMEM, Life Technologies, UK) supple-
mented with 10% fetal bovine serum (FBS), 1% L-glutamine,
and 1% penicillin/streptomycin.The cells were maintained at
37∘C in 5% CO2 incubator. To obtain an in vitro model that
represents the features ofDN, cells were divided into 3 groups:
(1) control, where cells were treated with DMEM medium
containing 5mM glucose and 1% FBS, (2) high glucose
treated, where cells were treated with DMEM medium con-
taining 30mM glucose and 1% FBS, and (3) osmotic control,
where cells were treated with DMEM medium containing
5mM glucose and 25mMmannitol with 1% FBS to simulate
amilieu that is osmotically equivalent to the 30mMhigh glu-
cose media. The cells were exposed to the above-mentioned
conditions for 24, 48, and 72 hours. To investigate the effects
of AR inhibition on high glucose-induced stress in renal
cells, NRK-52E cells were cotreated with epalrestat (Sigma
Aldrich, Germany) at 1 휇M concentration and compared
against vehicle-treated controls.
2.2. Assessment of Cell Viability. NRK-52E cells were seeded
on 96-well plates and treated according to the aforemen-
tioned protocol. At the end point, media were removed
and replaced by 100 휇l of fresh serum-free media and
10 휇l of 5mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent (Sigma Aldrich, Ger-
many). The plates were incubated at 37∘C for 3-4 hours.
The purple formazan crystals formed were solubilized in
50 휇l of dimethylsulfoxide (DMSO), and the absorbance was
measured at 570 nm using a microplate reader. Absorbance
value from the control group was set as 100% and the
values from treatment groups were expressed as percentage
of control.
2.3. Western Blotting. NRK-52E cells were seeded on 6-
well plates. At the end point, cells were scrapped and
lysed in 60mM Tris, pH 6.8 buffer containing 2% SDS.
Samples were sonicated for 10–15 seconds and centrifuged
at 16,000×g for 15 minutes at 4∘C prior to determination
of protein concentrations using bicinchoninic acid (BCA)
protein assay (Pierce, USA). About 20 to 40 휇g of protein
from each groupwas loaded onto 10%or 12% sodiumdodecyl
sulfate-polyacrylamide gels (SDS-PAGE) and resolved by
electrophoresis and transferred onto polyvinylidene fluoride
(PVDF) membranes. The membranes were blocked with
5% nonfat milk for 1 hour and then probed with specific
primary antibodies (overnight at 4∘C) for the following:
aldose reductase (ab131182 Abcam, 1 : 1000, mouse), p-Akt
(ab81283 Abcam, 1 : 2000, rabbit), Akt (ab32505 Abcam,
1 : 2000, rabbit), p-ERK (9106 cell signaling, 1 : 1000, mouse),
and ERK (9102 cell signaling, 1 : 1000, rabbit). Subsequently,
membranes were incubated with horseradish peroxidase-
(HRP-) conjugated goat anti-mouse IgG (1 : 10,000; Abcam,
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Figure 1: Effect of high glucose (30mM) on NRK-52E cells viability and relative mitochondrial membrane potential. (a) Cell viability of
low passage number cells (P2–P6) after 24 h, 48 h, and 72 h exposure to high glucose as determined by MTT assay. Absorbance values
were normalized to control group and expressed as percentage Mean ± SEM (n = 4–7). ∗푃 < 0.05 compared to control 48 h. #푃 < 0.05
compared to control 72 h. (b) Effect of high glucose concentration on relative mitochondrial membrane potential in NRK-52E cells after 24
and 48 h exposure using JC-1 staining. Ratios obtained from fluorescence values of J-aggregates (excitation/emission 488/529 nm) and that of
monomers (excitation/emission 488/590 nm) were expressed as percentage Mean ± SEM (푛 = 3) compared to control. ∗푃 < 0.05 compared
to control 24 h.
UK) or goat anti-rabbit IgG (1 : 20,000; Abcam, UK) sec-
ondary antibodies for 1 hour at room temperature. The
immunoreactivity was visualized with Optiblot ECL detec-
tion kit (Abcam, UK) using Syngene (G-BOX Chemi XX6)
imaging system and analyzed using Scion Image software.
The densitometry values were normalized to actin (used as
loading control) and expressed as percentage of control.
2.4. Assessment of Mitochondrial Membrane Potential (JC-1
Assay). The high glucose-induced alterations in the mito-
chondrial membrane potential in NRK-52E cells were
assessed using JC-1 (5,5耠,6,6耠-tetrachloro-1,1耠,3,3耠 tetraethyl-
benzimidazolylcarbocyanine iodide; T-3168, Life Technolo-
gies, UK) as described previously [31]. Briefly, after 24 or 48 h
high glucose treatment, cells were stained with JC-1 reagent
(10 휇M) for 30 minutes at 37∘C in dark, and the fluores-
cence was measured using a microplate reader (SpectraMax,
USA) at excitation/emission (Ex/Em) 488 nm/529 nm to
measure monomers and Ex/Em 488 nm/590 nm to mea-
sure J-aggregates. The ratio of fluorescent intensity of J-
aggregates (red) to that of monomers (green) was calculated
to determine changes in mitochondrial membrane potential.
For fluorescence microscopy, cells were stained with JC-1 as
described above and imaged under fluorescent microscope
(Olympus, USA) with TRITC filter at 200x magnification.
2.5. Cell Cycle Analysis. Following 24 or 48 h high glucose
treatment, NRK-52E cells were fixed in 70% ethanol and kept
at −20∘C. On the day of analysis, cells were pelleted out by
centrifugation at 1000×g for 5 minutes at 4∘C and stained
with Tali! cell cycle solution (Life Technologies, UK) in dark
for 30 minutes to achieve a cell density of 1 × 105–5 × 106
cells/ml for analysis using Tali image-based cytometer (Life
Technologies, UK).
2.6. Statistical Analysis. All values were calculated as a
percentage of control (5mM glucose-treated group) and
expressed asMean± SEM.One-wayANOVA test followed by
Tukey’s post hoc test was performed using GraphPad Prism 6
to detect statistical differences between groups. 푃 < 0.05 was
considered statistically significant.
3. Results
3.1. Effect of High Glucose on the Viability and Relative
MitochondrialMembrane Potential of Renal Proximal Tubular
Cells. NRK-52E cells were exposed to high glucose media
(30mM) for 24, 48, and 72 hours. 30mMmannitol was used
as osmotic control. At the endpoint, cell viability was assessed
by MTT assay. It was observed that when using cells at low
passage number (P2 to P6), there was a significant decrease
in viability after 48 hours to 84%, which further declined to
68% after 72 h (Figure 1(a)). Intriguingly, the high glucose-
induced decrease in viability after 48 and 72 h exposure was
not reproducible when using cells with passage numbers
higher than P7 (data not shown).Thus, we chose to perform
all experiments on NRK-52E cells between passage numbers
P2 to P6.
Alterations in the relative mitochondrial membrane
potential (Δ휓m) ofNRK-52E cells following exposure to high
glucose concentrations were assessed using JC-1 staining. JC-
1 is a cationic dye, which at high Δ휓m forms J-aggregate with
red fluorescence, while at low Δ휓m it remains as monomers
with green fluorescence. Therefore, the ratio of red to green
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Figure 2: Activation of Akt pathway in NRK-52E cells following exposure to high glucose for 10 minutes, 30 minutes, 1 hour, 2 hours, and
4 hours. (a) A representative western blot showing the expression of p-Akt and total Akt. (b) Bar graph showing densitometry data of p-Akt
expression normalized to total Akt expression. Values were expressed as percentage Mean ± SEM (푛 = 3) relative to control. ∗푃 < 0.05
compared to control.
fluorescence is indicative of the polarization status of the
mitochondria membrane. NRK-52E cells exposed to 30mM
glucose for 24 h and stainedwith JC-1 showed increased green
fluorescence, and the red to green fluorescence ratio was 81%
as compared to control. Although the mitochondrial depo-
larization was sustained after 48 h of high glucose exposure,
it was not statistically significant (Figure 1(b)).These findings
indicate that acute high glucose exposure induces transient
mitochondrial depolarization in renal tubular cells.
3.2. Effect of High Glucose on Akt and ERK Signaling Pathways
in Renal Tubular Cells. Activation of Akt and ERK signaling
pathways was investigated in renal tubular cells following
exposure to high glucose for 10 minutes, 30 minutes, 1 hour,
2 hours, and 4 hours. As shown in Figures 2 and 3, there was
an acute and transient induction of p-Akt and p-ERK after
10minutes of high glucose exposure, which then subsided at
further time points tested.
3.3. Effect of High Glucose on Aldose Reductase (AR) Expres-
sion in Renal Tubular Cells. To investigate if aldose reductase
(AR) was induced in the model, AR expression was mea-
sured in NRK-52E cells subjected to high glucose treatment.
Although the AR expression remained unchanged after 24
hours of high glucose treatment, it was significantly induced
at 48 hours by about 1.5-fold as compared to control (Fig-
ure 4). A small induction in AR protein expression was also
observed in cells exposed to high osmolar media (30mM
mannitol) at 48 hours.
3.4. Effect of Epalrestat on High Glucose-Induced Alterations in
Renal Cell Viability and Cell Cycle. To examine the protective
effect of aldose reductase (AR) inhibition on high glucose-
induced renal cell injury, NRK-52E cells were exposed to
high glucose in presence of 1휇M epalrestat (an AR inhibitor)
for 48 hours. At the endpoint, cell viability was measured
using MTT assay. As observed earlier, with 48 hours' high
glucose treatment, the cell viability declined to 84% (푃 <0.05) to that of control. In contrast, coincubation of cells with
epalrestat at 1 휇Mwas able to attenuate high glucose induced
cell death (Figure 5(a)). In addition, when cells were exposed
to high glucosemedium for 48 h in presence of epalrestat, the
percentage of cells increased in the G1 phase when compared
to control but was not statistically significant (Figure 5(b)).
3.5. Effect of Epalrestat on Mitochondrial Membrane Potential
Depolarization in Renal Tubular Cells. The effect of epalrestat
on the mitochondrial membrane potential in renal tubular
cells was assessed after 24 hours of high glucose exposure
using JC-1 staining. Coincubation of cells with 1휇Mepalrestat
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Figure 3: Activation of ERK signaling pathway assessed after exposing NRK-52E cells to high glucose medium for 10 minutes, 30 minutes,
1 hour, 2 hours, and 4 hours. (a) Representative western blots of p-ERK1/2 and ERK1/2. (b) Densitometric analysis for p-ERK1 and (c)
densitometric analysis for p-ERK2. Values were expressed as percentage Mean ± SEM (푛 = 3) relative to control. ∗푃 < 0.05 compared to
control.
reversed the depolarization observed with 24 hours' high
glucose treatment. Fluorescent cell images further confirmed
this finding, that is, an intense green staining observed in
high glucose-treated cells, whereas the cells coincubated with
epalrestat show a mixed red and green staining pattern
similar to control cells (Figure 6).
3.6. Effect of Epalrestat on High Glucose-Induced Activation
of Akt and ERK Pathways in Renal Tubular Cells. NRK-
52E cells were exposed to 10 minutes of high glucose in
presence of epalrestat to investigate the effect of aldose
reductase inhibition on high glucose-induced activation of
Akt and ERK pathways. As seen in Figure 7, epalrestat
cotreatment attenuated high glucose-mediated induction of
Akt and ERK pathways, which suggests crosstalk between
these two pathways and the polyol pathway in renal cells
under high glucose conditions.
4. Discussion
Our studies indicate that exposure of NRK-52E cells to
30mM glucose causes a progressive decline in cell viability,
that is, 84% viability after 48 hours and 68% viability after 72
hours as compared to control (100%). Similarly, a study by
Park et al. using primary rabbit renal proximal tubular cells
observed inhibition of cell proliferation over 24, 48, and 72
hours following exposure to 25mM glucose [32]. It has been
shown that high glucose induces mitochondrial alterations
and dysfunction, which ultimately leads to apoptosis. In the
current study, the effect of high glucose on mitochondrial
membrane potential was tested in NRK-52E cells using JC-
1 dye. After 24 hours, there was a slight decrease (81%
compared to control) in mitochondrial membrane potential,
which was sustained at 48 h (86% compared to control)
indicating that high glucose treatment inducesmitochondrial
membrane depolarization in renal tubular cells. Our finding
is in line with other studies, which demonstrated the onset
of mitochondrial dysfunction in human kidney cells (HK-2)
following exposure to high glucose medium [33–35]. There-
fore, these findings suggest that tubular cell death observed
in the current model might be initiated by alterations in
mitochondrial function.
PI3K/Akt pathway is a vital pathway that is implicated
in numerous cellular processes [36]. Several studies have
revealed impairments in the PI3K/Akt pathway during dia-
betes and signified its role in the development of diabetic
complications [8, 37, 38]. For example, hyperglycemia has
been shown to induce collagen-I synthesis in mesangial
cells by stimulating cytokines such as TGF-훽 and epidermal
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Figure 4: Effect of high glucose (30mM) on aldose reductase (AR) expression in NRK-52E cells after 24 and 48 h as measured by western
blotting. (a) A representative western blot showing the expression of AR in comparison to the loading control 훽-actin. (b) Bar graph with
densitometric analysis of AR expression (normalized to 훽-actin). Values were expressed as percentageMean ± SEM (푛 = 3) relative to control.∗푃 < 0.05 compared to control.
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Figure 5: Effects of epalrestat on high glucose-induced renal cell injury and cell cycle progression. (a) Cell viability of NRK-52E cells after
exposure to high glucose with and without 1 휇M epalrestat for 48 h as determined by MTT assay. Values were expressed as percentage Mean± SEM (푛 = 3) relative to vehicle-treated control. ∗푃 < 0.05 compared to control. (b) Distribution of NRK-52E cells along cell cycle after
incubation with high glucose and mannitol in the presence or absence of epalrestat (1휇M). Summarized data were reported in Table 1.
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Table 1: Cell cycle analysis (using Tali image-based cytometer) of NRK-52E cells exposed to 30mM glucose or osmotic control media with
or without epalrestat (1 휇M) for 48 h.
Treatment groups Percentage of cells at different stages of cell cycle
G1 S G2
Vehicle-treated control 51.5 ± 1.2 27.75 ± 5.5 19.25 ± 3.5
Vehicle-treated high glucose 59 ± 2 27.33 ± 4.7 13 ± 5.6
Vehicle-treated osmotic control 71.5 ± 4.5 23 ± 5 4 ± 0.1
Control + 1 휇M epalrestat 49.75 ± 3.7 26 ± 5.9 21.25 ± 5.9
High glucose + 1 휇M epalrestat 61.5 ± 3.9 23.5 ± 5.2 14.5 ± 3.1
Osmotic control + 1 휇M epalrestat 62.67 ± 4.3 22.33 ± 6.3 15.67 ± 3.9
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Figure 6: Assessment of relative mitochondrial membrane potential in NRK-52E cells by JC-1 staining. (a) Bar graph showing fluorescence
values after 24 h of high glucose exposure with and without 1 휇M epalrestat using JC-1 staining. Values were expressed as percentage Mean ±
SEMof J-aggregate (excitation/emission 488/529) tomonomer (excitation/emission 488/590) ratio compared to control. ∗푃 < 0.05 compared
to control. (b) Representative JC-1 stained images of NRK-52E cells treated with high glucose and osmotic control media in the presence or
absence of 1휇M epalrestat visualized under 400x magnification using fluorescence microscope.
growth factor (EGF) through PI3K/Akt dependent pathway
[37, 39].
In this study, exposing NRK-52E cells to 30mM glucose
caused acute activation of S473-phosphorylated Akt after 10
minutes of exposure, which then subsided at higher time
points (30 minutes, 1 h, 2 h, and 4 h). This finding was
consistent with other findings previously described in the
literature where high glucose activates Akt pathway in renal
cells [9, 40].
ERK1/2 pathway is a major pathway that is actively
involved in regulation of cellular functions. It has been shown
that mitogen-activated protein kinase (MAPK) cascade was
activated in glomerular mesangial cells exposed to high glu-
cose concentrations as well as in diabetic rats’ glomeruli [41].
Furthermore, inhibiting ERK 1/2 pathway in mesangial cells
in vitro attenuated high glucose-induced TGF-훽1 expression
and the induction of collagen-I and fibronectin mRNA [42,
43]. In addition, in vitro studies using renal tubular cells
showed that ERK1/2 pathway is implicated in high glucose-
induced TGF-훽1, fibronectin, and collagen-IV expression as
well as tubular cell hypertrophy [44, 45]. In the current study,
high glucose treatment induced acute phosphorylation of
ERK1/2 within 10 minutes of exposure in renal tubular cells.
Taken together, these findings provide evidence for the role of
ERK1/2 pathway in the development and progression of DN.
Findings from this study indicate that exposing tubular
cells to high glucose concentrations in vitro induces low levels
of cellular stress and injury, which is not unexpected given the
complexity ofmechanisms involved in diabetic complications
and the inherent limitations of in vitro high glucose model
to mimic diabetic setting. To establish an in vitro model of
DN within a reasonable time frame, culturing cells at high
glucose concentrations are commonly employed [32, 46].
Alternatively, cells could be transfected with markers of DN
such as angiotensin II and TGF-훽1 to aggravate DN in vitro.
Additionally, albumin can be used in conjunction with high
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Figure 7: NRK-52E cells were exposed to high glucose (HG) with and without epalrestat (EPS) for 10 minutes and assessed for its effect
on Akt and ERK pathways. Left panel showing representative blots for Akt and ERK1 and ERK2, and the right panel showing densitometric
analysis of the bands. Values were expressed as Mean ± SEM (푛 = 3). ∗푃 < 0.05 compared to control; ∗∗푃 < 0.05 compared to HG-treated
group.
glucose to mimic advanced stages of DN [47]. Serum (FBS)
concentration is another crucial factor in the development
of an in vitro DN model. In our model, serum deprivation
has greatly affected the growth and morphology of NRK-52E
cells, and consistent results were obtained when cells were
exposed to 30mM glucose media containing 1% FBS for 24
and 48 hours.
It has been shown that activation of polyol pathway
due to hyperglycemia in renal cells plays a pivotal role in
the development of DN [48]. Therefore, it is hypothesized
that inhibiting aldose reductase enzyme, the rate-limiting
enzyme in the polyol pathway, can protect the cells against
high glucose-induced cell injury in renal tubular cells [49].
Activation of polyol pathway in response to high glucose
has been reported to cause a sevenfold increase in sorbitol
production in renal proximal tubules [50]. Our results reveal
that aldose reductase expression was increased by about 1.5-
fold with high glucose treatment as compared to control at 48
hours. Similar inductions of AR protein expression have been
reported in studies using mesangial cells cultured under high
glucose conditions [29, 48].
Coincubation of NRK-52E cells with 1 휇M epalrestat
(dose based on the literature [34] and our pilot studies)
has prevented mitochondrial depolarization and loss of cell
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viability induced by high glucose.These findings suggest that
AR inhibition can protect renal cells against high glucose-
induced mitochondrial alterations and improve cell survival.
In addition, cell cycle analysis was performed to determine
the effects of high glucose on cell cycle progression. Our
results showed that incubation with high glucose for 48 h
increased the proportion of cells in G1 phase as compared to
control (59% versus 51%, resp.). Consistent with our findings,
a similar G1 phase arrest has been observed in other studies
using different types of renal tubular cells [8]. Together, these
findings suggest that tubular renal cell hypertrophy occurs in
cell cycle-dependent manner [8, 32, 51].
Although treatment with epalrestat did not block the
effects of high glucose on cell cycle in our model, it ame-
liorated high glucose-mediated acute activation of Akt and
ERK pathways. As mentioned earlier, both pathways are
actively involved in DN and contribute to development of
many of its pathologic features.Therefore, our results suggest
that AR inhibition exerts a protective effect on kidney cells
through attenuation of Akt and ERK dependent pathways.
This finding is in line with another study, which showed that
transfecting mesangial cells with AR gene augmented high
glucose-mediated activation of Akt and ERK pathways in
these cells [29].
In support to our findings, inhibiting aldose reductase has
been shown to reverse high glucose-induced production of
ECM proteins such as fibronectin [29]. Nevertheless, specific
inhibition of aldose reductase with enzyme inhibitors is
extremely challenging due to its extensive homology with
other aldo-keto reductase family members and makes it
hard to find specific inhibitors that are devoid of properties
to block other aldo-keto enzymes involved in protective
physiological detoxification of toxic aldehydes formed within
cells.
5. Conclusions
In summary, in vitro exposure to high glucose acutely
activates Akt and ERK pathways and induces pathologic
changes such as decreases in cell viability and depolariza-
tion of mitochondrial membrane potential in renal tubular
cells (Figure 8). These pathologic alterations in signaling
pathways and cellular organelles initiated by hyperglycemia
could potentially contribute to high glucose-induced renal
injury. Most importantly, our studies demonstrate that polyol
pathway plays a crucial role in development of renal tubular
cell injury in a high glucose milieu, and inhibiting its rate-
limiting enzyme aldose reductase (AR) protects renal cells
against high glucose-mediated deleterious effects (Figure 8).
Further studies in vitro and in vivo are required to ascertain
their therapeutic potential of AR inhibitors to prevent and/or
treat DN.
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